• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Lynn Yoffee

Lynn Yoffee

lynn.yoffee@clarivate.com
Articles

ARTICLES

Group of multigenerational, multiracial women

Healing a health divide (that’s long overdue)

Nov. 14, 2024
By Lynn Yoffee
It’s difficult to fathom that the health of half the world’s population is underserved. But it’s a hard truth. There are many conditions that disproportionately impact women. Other conditions and diseases affect women in different ways than men. Decades of research excluding women from clinical trials and investment decisions in male-dominated board rooms have ignored these facts. Though an increasing number of women are now managing investments and driving the research, it’s all still woefully behind. In BioWorld’s new report, Healing the health divide, we’ve highlighted the disparities.
Read More

Welcome to the new BioWorld site

Award-winning news and analysis … enhanced
Nov. 8, 2019
By Lynn Yoffee

More drug pricing red tape or potential solutions?

Oct. 17, 2016
By Lynn Yoffee
Unpacking the complex U.S. drug pricing system to fix it starts with understanding how it works. It's become clear that many who make the rules are woefully unclear about a system that's rife with a lack of transparency, multilevel negotiations, hidden markups, cost shares, usual and customary prices, and a host of patient assistance programs (PAPs).
Read More

Ethically speaking: What’s the right thing to do?

July 29, 2016
By Lynn Yoffee
The challenges of drug development are vast and demanding. Keeping up with scientific advances, the competition, clinical trial roller coasters, global regulatory hurdles, financing innovation, pricing … the list is endless. But have the myriad responsibilities distracted us from the assumed main reason for developing new medicines? Is improving the human condition in a way that prioritizes the largest problems first too lofty a goal? What risks should sick patients take in the name of science and who is protecting the vulnerable? Who decides what’s right and safe in tinkering with our genetic makeup? Though watchdogs aplenty monitor various parts...
Read More

The epic failure to achieve diversity in clinical trials persists

Nov. 25, 2014
By Lynn Yoffee
Patients are astonished when they learn that the development of most drugs has, historically, not incorporated human differences into the design equation. How and why age, ethnicity, gender and race haven't been woven into most clinical trial designs makes most people in the industry cringe because the issue is immensely complicated.
Read More

BioWorld Reports from 2014 ASCO Meeting

June 5, 2014
By Lynn Yoffee
If you were overwhelmed trying to keep up with our breaking news bulletins and massive daily editions during this year's American Society of Clinical Oncology (ASCO) meeting, never fear. We've collected them all in a special ASCO 2014 report. (For the full report, see today's PDF edition of BioWorld Today.) We hope this is a valuable resource as you all push forward in attempts to conquer the insidious unregulated cell growth which makes up the collection of diseases, cancer.
Read More

Hong Kong biotech debuts at JPM, seeks investors for cancer drug

Jan. 21, 2014
By Lynn Yoffee
SAN FRANCISCO – With a magnificent view of the early morning San Francisco skyline from the 32nd floor of the Westin St. Francis, Paul Cheng, CEO, chief scientific officer and founder of Hong Kong-based Bio-Cancer Treatment International Ltd., kicked off the emerging markets track of the J.P. Morgan Healthcare conference last week with a talk about how his little company is aiming big guns at hepatitis B-induced hepatocellular carcinoma (HCC) – the third leading cause of cancer death in China.
Read More

JPM’s emerging markets presenters surf challenging waves

Jan. 21, 2014
By Lynn Yoffee
SAN FRANCISCO – 2013 was not the best PR year for biopharmaceutical companies in Asia. The vast potential for success by doing business in those markets is complicated after a frenzied growth mode and now executives are faced with challenges of managing those businesses since bribery and corruption scandals have rocked Glaxosmithkline plc.
Read More

John Oyler Aims To Build China’s Genentech via Beigene

Nov. 27, 2013
By Lynn Yoffee
BEIJING – Just a few days after Beigene Co. Ltd.’s CEO and co-founder John Oyler signed a second sizable deal with the Merck Serono arm of Merck KGaA – the up-front payments undisclosed, but with a promise of almost $500 million if all milestones are achieved in both – he admitted the cash removes a layer of stress: “Maybe you sleep better at night, but it’s business as usual. The deal with Merck doesn’t change the way you work or the passion.”
Read More

John Oyler Aims To Build China’s Genentech via Beigene

Nov. 22, 2013
By Lynn Yoffee
BEIJING – Just a few days after Beigene Co. Ltd.’s CEO and co-founder John Oyler signed a second sizable deal with the Merck Serono arm of Merck KGaA – the up-front payments undisclosed, but with a promise of almost $500 million if all milestones are achieved in both – he admitted the cash removes a layer of stress: “Maybe you sleep better at night, but it’s business as usual. The deal with Merck doesn’t change the way you work or the passion.”
Read More
View All Articles by Lynn Yoffee

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 26, 2025.
  • Martin Kulldorf, ACIP chair

    No vote, ACIP recurring theme at CDC confirmation hearing

    BioWorld
    Although the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) was scheduled to vote June 25 on recommendations for maternal and pediatric...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • Hands holding gears

    Kymera brings on Gilead as partner while Sanofi alters deal

    BioWorld
    Kymera Therapeutics Inc. found itself juggling partnerships by bringing one on board while going to the development bench in another. Kymera and Gilead Sciences...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe